Cubist Pharmaceuticals, Inc. (NASDAQ:CBST)

CAPS Rating: 4 out of 5

A biopharmaceutical company focused on the research, development and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment.


Player Avatar BrentonKJ (27.36) Submitted: 10/13/2012 2:22:24 PM : Outperform Start Price: $45.99 CBST Score: -1.39

IBD pick. Good growth prospects and not too expensive compared to peers.

Featured Broker Partners